The first embryo's stem cell's human clinical trial in the

The first embryo's stem cell's human clinical trial in the world is criticized
On July 30, American food medicines supervise the administration bureau notifying Geron Company, accept its new medicines to develop (IND) Clinical practice is applied for, GRNOPC1 the first stage of clinical trial that Geron Company can advance the acute spinal to damage the patient. This makes Geron Company qualified to advance the first human clinical trial based on person's embryo's stem cell in the world. Geron Company says, first issue and more than centres test and damage the association and cooperate with the American backbone, the therapeutic sub-acute chest spinal with impairment scale of A is damaged, so as to ensure to set up the patient GRNOPC1's security. "We damage and employ the goal of GRNOPC1 to never the sub-acute spinal change - -Dash for ward little colloid grandfather's cells through injecting people's embryo's stem cell's source, damage the patient's sick position to the spinal directly, in order to meet the target of resuming the spinal function. In addition, we begin to explore the utility of GRNOPC1 in other regression central nervous system illness formally, for instance, Alzheimer's ill, multiple sclerosis and malnutritive disease of white matter of the spongy brain. " President Thomas B of Geron Company. Okarma expresses. GRNOPC1 is the first-selection in stem cell's candidate scheme of basic treatment of embryo of people of Geron Company, its stem cell's source of embryo of person that contains dash for ward little colloid grandfather's cells and already confirm possessing and promoting the characteristic of reconstructing neural ball and nerve to grow, can cause the acute spinal to damage animal's model function to resume. "The group of department of neurosurgery has already determined to begin to treat the clinical trial that the destructive spinal damages the new method. All of us know the myelin take off and lose and damage the pathological central topic, inject the method and can reverse through dashing for ward little colloid grandfather's cells, the method field this loud to innovate, confirm security and validity its, this kind of treatment will offer a feasible healing solution choice for the fact that thousands of serious disease spinals of every year will damage a patient. " The professor Richard Fessler of American department of neurosurgery of medical institute of Northwest University says. (Ji RongXia /compile)
The first embryo's stem cell's human clinical trial in the world is criticized